

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
FRAMEWORK AGREEMENT WITH ASTRAZENECA

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that the Group has entered into a Framework Master Product Supply Agreement (the “**Framework Agreement**”) dated August 7, 2023 with AstraZeneca AB (the “**AstraZeneca**”), pursuant to which the Group will from time to time provide certain products and/or related services to AstraZeneca to support the research & development of certain vaccines by using the Group’s mRNA manufacturing platform (the “**Program**”), whereby the Group will manufacture and supply certain products, and provide certain related services to AstraZeneca for the Program.

BACKGROUND

The Group has extensive experience and proven capabilities in developing, manufacturing and commercializing innovative vaccine products. AstraZeneca is researching mRNA vaccines. The proposed cooperation between the Group and AstraZeneca will focus on the research & development of certain vaccines of AstraZeneca by using the Group’s mRNA manufacturing platform.

FRAMEWORK AGREEMENT

Agreement Date: August 7, 2023

Parties: (i) The Group, as the supplier; and
(ii) AstraZeneca, as the purchaser

Term: The term of the Framework Agreement commences from August 7, 2023 to the later of (i) the tenth (10th) anniversary of August 7, 2023 or (ii) the expiration of the last-to-expire product supply schedule then in effect.

Each product supply schedule shall commence on its effective date and remain in force for the term of the Framework Agreement, or as otherwise provided in such product supply schedule, unless terminated earlier under the Framework Agreement or any applicable termination provisions provided in such product supply schedule.

Performance: **The Group's performance:** the Group shall carry out the Supply Services for each Product in accordance with (i) the Framework Agreement; (ii) each applicable product supply schedule; (iii) the purchase orders under each applicable product supply schedule; and (iv) the quality assurance agreement. The Group shall inform AstraZeneca promptly in writing of any event that, in the Group's reasonable judgment, may adversely affect the Group's ability to perform its obligations under the Framework Agreement.

AstraZeneca's performance: AstraZeneca shall pay the price pursuant the Framework Agreement and as specified in each product supply schedule. AstraZeneca shall, at its own cost, be solely responsible for the Product's safety evaluation.

Capacity Reservation: The Group shall reserve and make available to AstraZeneca sufficient capacity at the Group's manufacturing facility to enable the Group to manufacture and supply toxicology research and clinical research materials to AstraZeneca for certain mRNA vaccine products.

Delivery: The Group shall deliver the Products ordered on the delivery date stipulated and in accordance with the supply and stock management process in the applicable product supply schedule, and shall not deliver the Products before the delivery date stipulated unless AstraZeneca has given its prior written consent.

Other Arrangements: Unless otherwise provided in the Framework Agreement or in any applicable product supply schedule, the terms and conditions of the Framework Agreement shall govern each product supply schedule, and each product supply schedule shall form a separate agreement by incorporating the Framework Agreement in connection with the Supply Services for a specific Product defined therein. In case of any conflict between the terms of the Framework Agreement and any product supply schedule, the applicable terms of the product supply schedule shall apply.

REASONS FOR AND BENEFITS OF THE FRAMEWORK AGREEMENT

The board (the "**Board**") of directors of the Company (the "**Directors**") is of the view that the entering into of the Framework Agreement demonstrates the recognition of the Group's capabilities by biopharmaceutical multinational corporations and affirms the Group's research & development strengths and competitive advantages in mRNA technology platform, which is conducive to the further expansion of the Group's mRNA manufacturing platform. The Board considers that the transactions contemplated under the Framework Agreement are in the usual course of business for the Group and the terms of the Framework Agreement are based on normal commercial terms, and are fair and reasonable and in the interests of the Group and its shareholders as a whole.

OTHER INFORMATION

In addition to the Framework Agreement, the Group and AstraZeneca may further cooperate in research & development and commercialization of related products in the future (“**Further Cooperation**”). The Board wishes to emphasize that the Further Cooperation is subject to entering into definitive and legally binding agreements, the terms and conditions of which have yet to be negotiated and agreed. The Company will make further announcements in relation to the Further Cooperation and comply with all applicable requirements under the Listing Rules as and when necessary.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, August 8, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.